Literature DB >> 9447901

Comparison of two regimens for ciprofloxacin treatment of enteric infections.

C Agalar1, S Usubütün, E Tütüncü, R Türkyilmaz.   

Abstract

A clinical trial was conducted in 50 patients with blood cultures positive for Salmonella typhi or Salmonella paratyphi to compare treatment with ciprofloxacin for seven days, 500 mg b.i.d. (Group 1, 25 patients), with treatment for ten days, 750 mg b.i.d. (Group 2, 25 patients). Clinical cure was defined as defervescence of fever by day 5 of treatment, with an absence of complications and no clinical relapse. The clinical cure rate was 84% for group 1 and 96% for group 2; the difference in these rates was not statistically significant. The blood cultures of all patients were sterile by day 2 of treatment and remained so until the sixth month of follow-up. It was concluded that ciprofloxacin treatment for ten days in enteric fever is not necessary. Further studies are needed to evaluate the efficacy of shortening the duration of antibiotic therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9447901     DOI: 10.1007/bf01700409

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

Review 1.  Quinolone antibiotics in the treatment of Salmonella infections.

Authors:  M O Asperilla; R A Smego; L K Scott
Journal:  Rev Infect Dis       Date:  1990 Sep-Oct

2.  Comparative study of ciprofloxacin versus co-trimoxazole in the treatment of Salmonella enteric fever.

Authors:  B M Limson; R T Littaua
Journal:  Infection       Date:  1989 Mar-Apr       Impact factor: 3.553

3.  Short-term ciprofloxacin therapy for typhoid fever.

Authors:  C Carbon; P Weber; M Levy; Y Boussougant; M Cerf
Journal:  J Infect Dis       Date:  1987-04       Impact factor: 5.226

4.  Treatment of multiresistant Salmonella typhi with oral ciprofloxacin.

Authors:  S J Eykyn; H Williams
Journal:  Lancet       Date:  1987-12-12       Impact factor: 79.321

5.  Open study of ciprofloxacin in enteric fever.

Authors:  P J Stanley; P J Flegg; B K Mandal; A M Geddes
Journal:  J Antimicrob Chemother       Date:  1989-05       Impact factor: 5.790

6.  Treatment of typhoid fever: randomized trial of a three-day course of ceftriaxone versus a fourteen-day course of chloramphenicol.

Authors:  G Acharya; T Butler; M Ho; P R Sharma; M Tiwari; R K Adhikari; J B Khagda; B Pokhrel; U N Pathak
Journal:  Am J Trop Med Hyg       Date:  1995-02       Impact factor: 2.345

Review 7.  Quinolones in Salmonella typhi infection.

Authors:  H L DuPont
Journal:  Drugs       Date:  1993       Impact factor: 9.546

8.  Open, prospective study of the clinical efficacy of ciprofloxacin.

Authors:  C A Ramirez; J L Bran; C R Mejia; J F Garcia
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Comparison of ofloxacin and ceftriaxone for short-course treatment of enteric fever.

Authors:  M D Smith; N M Duong; N T Hoa; J Wain; H D Ha; T S Diep; N P Day; T T Hien; N J White
Journal:  Antimicrob Agents Chemother       Date:  1994-08       Impact factor: 5.191

  9 in total
  3 in total

Review 1.  Quinolones in the treatment of typhoid fever.

Authors:  H E Akalin
Journal:  Drugs       Date:  1999       Impact factor: 9.546

Review 2.  Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections.

Authors:  John A Crump; Maria Sjölund-Karlsson; Melita A Gordon; Christopher M Parry
Journal:  Clin Microbiol Rev       Date:  2015-10       Impact factor: 26.132

3.  Recurrent paratyphoid fever A co-infected with hepatitis A reactivated chronic hepatitis B.

Authors:  Yanling Liu; Yujiao Xiong; Wenxiang Huang; Bei Jia
Journal:  Ann Clin Microbiol Antimicrob       Date:  2014-05-12       Impact factor: 3.944

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.